Axim Biotechnologies Inc (AXIM)

[scoobey-do]

ii. AXIM® Biotechnologies, Inc. (Approximate 38% common equity ownership) per the current 10-Q

AXIM® Biotechnologies, Inc. (“AXIM®” - OTCBB: AXIM). AXIM® is an innovative biotechnology company working on the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids based products as well as focusing on research, development and production of pharmaceutical, nutriceutical, oral health and cosmetic products as well as procurement of genetically and nano-controlled active ingredients. AXIM® intends to broaden its current operations to include pharmaceutical products, manufacturing facilities, genetically controlled botanical products, extraction and purification of biomaterials technologies.

https://backend.otcmarkets.com/otcapi/company/financial-report/221055/content
From MJNA's 2019 10-Q, Page 7.

On March 31, 2018, MJNA stated that their held 42% of AXIM.